About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker AZN · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026An Efficacy and Safety Study to Assess an Inhaled, Fixed-dose, Budesonide/Formoterol Fumarate in Pa…
NCT07934420 · Asthma
BFF MDI, BD MDI
AZN
AstraZeneca
Phase 3Not yet recruiting216Jul 30, 2029Registry ↗
Nov 13, 2026A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD…
NCT07812077 · Healthy Participants
[14C]AZD4954 Oral Solution, AZD4954 film-coated tablet
AZN
AstraZeneca
Phase 1Recruiting
was not yet recruiting
16Mar 17, 2027Registry ↗
Nov 13, 2026Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic…
NCT07654855 · Transthyretin Amyloidosis, Transthyretin Amyloidosis With C…
None ( observational study )
AZN
AstraZeneca
—Recruiting320Jan 29, 2032Registry ↗
Nov 13, 2026Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fa…
NCT07444567 · Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Benralizumab
AZN
AstraZeneca
Phase 3Recruiting230Dec 27, 2029Registry ↗
Nov 13, 2026A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve a…
NCT07430306 · Systemic Lupus Erythematosus
Anifrolumab
AZN
AstraZeneca
Phase 3Recruiting245Jan 26, 2029Registry ↗
Nov 13, 2026Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Ly…
NCT07109219 · B-cell Acute Lymphoblastic Leukemia (B-ALL)
AZD4512 monotherapy
AZN
AstraZeneca
Phase 1/2Recruiting83Oct 11, 2028Registry ↗
Nov 13, 2026Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia
NCT07088991 · Neurofibromatosis
AZN
AstraZeneca
—Recruiting200Mar 31, 2028Registry ↗
Nov 13, 2026A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dysl…
NCT06834932 · Dyslipidaemia
Placebo, Rosuvastatin Dose 1
AZN
AstraZeneca
Phase 2/3Active, not recruiting432Feb 22, 2027Registry ↗
Nov 13, 2026Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid…
NCT06218914 · Non-small Cell Lung Cancer, Colorectal Carcinoma
NT-112: Autologous, engineered T Cells targeting KRAS G12D,…
AZN
AstraZeneca
Phase 1Active, not recruiting
was recruiting
108Aug 30, 2027Registry ↗
Nov 13, 2026A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreate…
NCT05057494 · Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Acalabrutinib, Venetoclax
AZN
AstraZeneca
Phase 3Active, not recruiting607Jul 15, 2027Registry ↗
Nov 13, 2026Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
NCT03953300 · Asthma
Benralizumab, Placebo
AZN
AstraZeneca
Phase 4Completed
was active, not recruiting
75Oct 20, 2026Registry ↗
Nov 12, 2026Changes in Symptom and Quality of Life in Patients With Uncontrolled Asthma Treated With Budesonide…
NCT07933510 · Asthma, Uncontrolled Asthma
Budesonide/Glycopyrronium/Formoterol fumarate metered dose…
AZN
AstraZeneca
—Not yet recruiting200Aug 31, 2027Registry ↗
Nov 12, 2026A Modular, Phase I/II Study to Evaluate CT204V-CD19 x CD20 in Participants With Relapsed or Refract…
NCT07932496 · Relapsed or Refractory B-Cell Malignancies
CT204V-CD19 × CD20
AZN
AstraZeneca
Phase 1/2Not yet recruiting160Oct 15, 2029Registry ↗
Nov 12, 2026A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat,…
NCT07930507 · Hypercholesterolemia
Laroprovstat, Rosuvastatin 1
AZN
AstraZeneca
Phase 3Not yet recruiting204Oct 11, 2027Registry ↗
Nov 12, 2026A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatm…
NCT07520162 · Chronic Rhinosinusitis With Nasal Polyps
Tezepelumab
AZN
AstraZeneca
Phase 3Recruiting230Mar 1, 2028Registry ↗
Nov 12, 2026A Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Partici…
NCT07024823 · Chronic Kidney Disease
AZD4248, Placebo
AZN
AstraZeneca
Phase 1Recruiting192Jan 29, 2027Registry ↗
Nov 12, 2026REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER
NCT06826677 · Small Cell Lung Carcinoma
Durvalumab
AZN
AstraZeneca
—Completed71Jan 23, 2025Registry ↗
Nov 12, 2026AZD5305 hADME in Patients With Advanced Solid Malignancies
NCT06713369 · Locally Advanced or Metastatic Solid Tumor
Saruparib (AZD5305), [14C]-AZD5305 microtracer
AZN
AstraZeneca
Phase 1Recruiting8Dec 31, 2026Registry ↗
Nov 12, 2026Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phe…
NCT06566885 · Severe Asthma
AZN
AstraZeneca
—Completed
was active, not recruiting
125Oct 20, 2026Registry ↗
Nov 12, 2026A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/…
NCT06015737 · Cutaneous Lupus Erythematosus
Anifrolumab, Placebo
AZN
AstraZeneca
Phase 3Active, not recruiting339Nov 2, 2026Registry ↗
Nov 12, 2026Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Ne…
NCT04924608 · Neurofibromatosis 1, Plexiform Neurofibroma (PN)
Selumetinib, Placebo
AZN
AstraZeneca
Phase 3Active, not recruiting145Aug 5, 2024Registry ↗
Nov 12, 2026A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advan…
NCT04739761 · Breast Cancer
Trastuzumab Deruxtecan
AZN
AstraZeneca
Phase 3Active, not recruiting506Feb 8, 2024Registry ↗
Nov 12, 2026A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
NCT03742102 · Triple Negative Breast Neoplasms
Durvalumab, Capivasertib
AZN
AstraZeneca
Phase 1/2Active, not recruiting243Nov 29, 2024Registry ↗
Nov 10, 2026Tezepelumab CRSwNP Real World Study (CREW Study)
NCT07790198 · Chronic Rhinosinusitis With Nasal Polyps
Tezepelumab
AZN
AstraZeneca
—Not yet recruiting100Sep 30, 2028Registry ↗
Nov 10, 2026Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saph…
NCT07691970 · Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lu…
Anifrolumab, Anifrolumab
AZN
AstraZeneca
Phase 3Recruiting1,072Dec 30, 2032Registry ↗
Nov 10, 2026A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Parti…
NCT07534592 · Healthy Participants
Elecoglipron, Atorvastatin
AZN
AstraZeneca
Phase 1Active, not recruiting48Jan 25, 2027Registry ↗
Nov 10, 2026A Study of AZD0120 in Autoimmune Diseases
NCT07295847 · Systemic Sclerosis, Idiopathic Inflammatory Myopathies
AZD0120, SOC
AZN
AstraZeneca
Phase 1/2Recruiting27Feb 22, 2028Registry ↗
Nov 10, 2026Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Adv…
NCT07291037 · Non-small Cell Lung Cancer (NSCLC)
Datopotamab deruxtecan (Dato-DXd), Docetaxel
AZN
AstraZeneca
Phase 3Recruiting400Jan 29, 2029Registry ↗
Nov 10, 2026Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
NCT07285213 · Clostridioides Difficile Infection
AZD5148, Placebo
AZN
AstraZeneca
Phase 2Recruiting230Apr 20, 2027Registry ↗
Nov 10, 2026Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With…
NCT07069829 · Chronic Obstructive Pulmonary Disease
AZN
AstraZeneca
—Recruiting1,400Dec 31, 2027Registry ↗
Nov 10, 2026Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerabi…
NCT06576765 · Hepatic Impairment
AZD0780
AZN
AstraZeneca
Phase 1Completed16Nov 8, 2024Registry ↗
Nov 10, 2026Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197 · Moderate to Severe Crohn's Disease
AZD7798, Placebo
AZN
AstraZeneca
Phase 2Active, not recruiting120Apr 30, 2026Registry ↗
Nov 10, 2026Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participa…
NCT06307665 · Asthma
BDA MDI, AS MDI
AZN
AstraZeneca
Phase 3Recruiting440Oct 13, 2027Registry ↗
Nov 10, 2026Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receivin…
NCT06120491 · Metastatic Castration-Sensitive Prostate Cancer
Saruparib, Placebo
AZN
AstraZeneca
Phase 3Active, not recruiting1,898Sep 30, 2027Registry ↗
Nov 10, 2026Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671 · Locally Advanced Cervical Cancer
Volrustomig, Placebo
AZN
AstraZeneca
Phase 3Recruiting800Nov 26, 2027Registry ↗
Nov 10, 2026A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 t…
NCT06023589 · Asthma
Tezepelumab, Placebo
AZN
AstraZeneca
Phase 3Recruiting231May 31, 2028Registry ↗
Nov 10, 2026A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metast…
NCT04995523 · Non-Small-Cell Lung Carcinoma
AZD2936
AZN
AstraZeneca
Phase 1/2Active, not recruiting212Jun 1, 2028Registry ↗
Nov 9, 2026Study of Safety and PK of AZD0543 in Healthy Adults
NCT07824622 · Human Metapneumovirus Infection
AZD0543, Placebo
AZN
AstraZeneca
Phase 1Recruiting144Mar 24, 2027Registry ↗
Nov 9, 2026A Study in Greece Observing How Patients With Stomach and Esophageal Cancer Are Diagnosed and Treat…
NCT07800754 · Gastric Cancer, Gastroesophageal Junction Cancer
AZN
AstraZeneca
—Recruiting300Dec 31, 2027Registry ↗
Nov 9, 2026A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participan…
NCT07776509 · Obesity or Overweight, Weight-Related Comorbidity
Lenbelintide, Placebo
AZN
AstraZeneca
Phase 3Recruiting500Aug 9, 2028Registry ↗
Nov 9, 2026A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity o…
NCT07775404 · Obesity, Overweight
Elecoglipron, Placebo
AZN
AstraZeneca
Phase 3Recruiting351Apr 6, 2028Registry ↗
Nov 9, 2026A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in He…
NCT07511205 · Healthy Participants, Obesity
AZD1043, Placebo
AZN
AstraZeneca
Phase 1Recruiting104Apr 9, 2027Registry ↗
Nov 9, 2026A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136 · Heterozygous Familial Hypercholesterolaemia
AZD0780, Placebo
AZN
AstraZeneca
Phase 3Active, not recruiting473Jan 4, 2027Registry ↗
Nov 9, 2026A Multicentre, Single Arm, Non-interventional, Real-world Study to Assess Demographic Characteristi…
NCT06862206 · Severe Eosinophilic Asthma
benralizumab
AZN
AstraZeneca
—Recruiting700Jan 31, 2028Registry ↗
Nov 9, 2026Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
NCT04157348 · Eosinophilic Granulomatous Vasculitis
Benralizumab, Mepolizumab
AZN
AstraZeneca
Phase 3Active, not recruiting140Aug 10, 2023Registry ↗
Nov 9, 2026Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unre…
NCT03833154 · Carcinoma, Non-Small-Cell Lung
Durvalumab, Placebo
AZN
AstraZeneca
Phase 3Active, not recruiting724Oct 31, 2028Registry ↗
Nov 9, 2026Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Lin…
NCT01933932 · Locally Advanced or Metastatic Non Small Cell Lung Cancer S…
Selumetinib, Docetaxel
AZN
AstraZeneca
Phase 3Active, not recruiting510Jun 7, 2016Registry ↗
Nov 6, 2026A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults…
NCT07922330 · Obesity, Overweight
AZD6234, Placebo
AZN
AstraZeneca
Phase 3Not yet recruiting330Sep 15, 2028Registry ↗
Nov 6, 2026A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in…
NCT07877818 · Gastric, Esophagogastric Junction
FLOT Chemotherapy, Durvalumab
AZN
AstraZeneca
Phase 3Recruiting
was not yet recruiting
140Nov 1, 2029Registry ↗
Nov 6, 2026Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination De…
NCT07851025 · Epithelial Ovarian Cancer
Torvutatug samrotecan, Bevacizumab
AZN
AstraZeneca
Phase 3Recruiting950Jun 28, 2030Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:53 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances